207_Combined course Presentations

DAHANCA 19: ART only, oropharynx, HPV/p16+

Loco-regional control

Overall survival

control 89%

control 80%

zalutumumab 76%

zalutumumab 74%

HR: 2.19 [95% CI: 0.55-8.77]

HR: 1.36 [95% CI: 0.42-4.46]

Pts. at risk Events

Pts. at risk Events

zalutumumab 24

6 3 9

zalutumumab 24

7 5

control

29 53

control

29 53

total

total

12

Eriksen 2015